MacroGenics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
MacroGenics (Nasdaq: MGNX) has announced its participation in two major investor conferences in November 2024. At the Guggenheim Securities Healthcare Innovation Conference in Boston, COO Eric Risser will lead a fireside chat on November 12 at 4:00pm ET. At the Stifel 2024 Healthcare Conference in New York, President & CEO Scott Koenig will conduct a fireside chat on November 18 at 1:15pm ET. Both events will include one-on-one meetings with management. The presentations will be webcast and available for 30 days on MacroGenics' investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – MGNX
In the trading session that priced this news, MGNX gained 6.44%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:
- Guggenheim Securities Healthcare Innovation Conference (Boston). MacroGenics’ Chief Operating Officer, Eric Risser, will participate in a fireside chat on Tuesday, November 12, 2024, at 4:00pm ET. MacroGenics’ management will also participate in one-on-one meetings.
- Stifel 2024 Healthcare Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Monday, November 18, 2024, at 1:15pm ET. MacroGenics’ management will also participate in one-on-one meetings.
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
